Revive Therapeutics Sees FDA Recommend Phase 3 For COVID-19 Related Study Of Bucillamine

Revive Therapeutics (CSE: RVV) announced major news this morning related to its ongoing study of Bucillamine, with the US Food and Drug Administration recommending that the company proceed straight to a phase three confirmatory clinical trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection.

The news is significant as it means that Revive will be able to skip over the phase two clinical study portion of the FDA’s process, enabling the product to get to market sooner than expected if proven effective against the infectious disease. The push to phase three on the study of Bucillamine will enable the company to expeditiously evaluate the safety and efficacy of the drug.

In addition to the recommendation provided, the FDA also provided guidance on the study design and outcome measures for the phase 3 study. More importantly, the FDA identified that as a result of Revive’s previous work with the drug on the treatment of gout, the data provided from that study could be used to skip over phase 1 and 2 of the clinical study process. The firms contract research team, Pharm-Olam, is actively working towards assembling the final investigation new drug (IND) for submission to the FDA within the next 60 days, after which the firm will begin its phase 3 trials.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Revive Therapeutics last traded at $0.18 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Rebound in Oil Demand Remains at Risk of Coronavirus Resurgence

As the global demand for oil dried up significantly during the height of the pandemic,...

Sunday, July 12, 2020, 07:17:00 PM

Biotech Boom Playbook, Part Two: The Structure

The degree to which a compelling biotech story is able to create lift in the...

Tuesday, May 26, 2020, 04:16:08 PM

GM Down to Two Shifts at Missouri Plant After Employees Stop Showing Up as Coronavirus Fears Mount

As coronavirus cases continue to rise at alarming levels across the US, many Americans have...

Tuesday, July 14, 2020, 07:45:00 PM

United States Breaks 4 Day Trend Of 1,000 COVID-19 Deaths A Day

The United States finally broke below the 1,000 deaths per day figure on Saturday, following...

Sunday, July 26, 2020, 03:45:00 PM

European Car Sales Drop by 76% in April Amid Coronavirus Lockdown

It appears that vehicle sales are not only struggling in the US amid the coronavirus...

Wednesday, May 20, 2020, 04:46:00 PM